These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35218775)

  • 1. Structure-guided affinity maturation of a single-chain variable fragment antibody against the Fu-bc epitope of the dengue virus envelope protein.
    Sarker A; Rathore AS; Khalid MF; Gupta RD
    J Biol Chem; 2022 Apr; 298(4):101772. PubMed ID: 35218775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.
    Smith SA; de Alwis AR; Kose N; Harris E; Ibarra KD; Kahle KM; Pfaff JM; Xiang X; Doranz BJ; de Silva AM; Austin SK; Sukupolvi-Petty S; Diamond MS; Crowe JE
    mBio; 2013 Nov; 4(6):e00873-13. PubMed ID: 24255124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct and indirect interactions in the recognition between a cross-neutralizing antibody and the four serotypes of dengue virus.
    Lisova O; Belkadi L; Bedouelle H
    J Mol Recognit; 2014 Apr; 27(4):205-14. PubMed ID: 24591178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
    Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
    J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing antibody against highly conserved region of dengue envelope protein by in silico screening of scFv mutant library.
    Rathore AS; Sarker A; Gupta RD
    PLoS One; 2019; 14(1):e0209576. PubMed ID: 30629625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III.
    Hu D; Zhu Z; Li S; Deng Y; Wu Y; Zhang N; Puri V; Wang C; Zou P; Lei C; Tian X; Wang Y; Zhao Q; Li W; Prabakaran P; Feng Y; Cardosa J; Qin C; Zhou X; Dimitrov DS; Ying T
    PLoS Pathog; 2019 Jun; 15(6):e1007836. PubMed ID: 31242272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.
    Costin JM; Zaitseva E; Kahle KM; Nicholson CO; Rowe DK; Graham AS; Bazzone LE; Hogancamp G; Figueroa Sierra M; Fong RH; Yang ST; Lin L; Robinson JE; Doranz BJ; Chernomordik LV; Michael SF; Schieffelin JS; Isern S
    J Virol; 2013 Jan; 87(1):52-66. PubMed ID: 23077306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human monoclonal single-chain antibodies specific to dengue virus envelope protein.
    Saokaew N; Poungpair O; Panya A; Tarasuk M; Sawasdee N; Limjindaporn T; Chaicumpa W; Yenchitsomanus P
    Lett Appl Microbiol; 2014 Mar; 58(3):270-7. PubMed ID: 24266517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1.
    Messer WB; Yount BL; Royal SR; de Alwis R; Widman DG; Smith SA; Crowe JE; Pfaff JM; Kahle KM; Doranz BJ; Ibarra KD; Harris E; de Silva AM; Baric RS
    J Virol; 2016 May; 90(10):5090-5097. PubMed ID: 26962223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
    Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes.
    Andrade DV; Katzelnick LC; Widman DG; Balmaseda A; de Silva AM; Baric RS; Harris E
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection.
    Tsai WY; Lai CY; Wu YC; Lin HE; Edwards C; Jumnainsong A; Kliks S; Halstead S; Mongkolsapaya J; Screaton GR; Wang WK
    J Virol; 2013 Dec; 87(23):12562-75. PubMed ID: 24027331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein.
    Tang CT; Liao MY; Chiu CY; Shen WF; Chiu CY; Cheng PC; Chang GJ; Wu HC
    PLoS One; 2015; 10(8):e0136328. PubMed ID: 26309127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection.
    Sukupolvi-Petty S; Brien JD; Austin SK; Shrestha B; Swayne S; Kahle K; Doranz BJ; Johnson S; Pierson TC; Fremont DH; Diamond MS
    J Virol; 2013 Aug; 87(16):8826-42. PubMed ID: 23785205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones.
    Smith SA; de Alwis AR; Kose N; Jadi RS; de Silva AM; Crowe JE
    J Virol; 2014 Nov; 88(21):12233-41. PubMed ID: 25100837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4
    Zaneti AB; Yamamoto MM; Sulczewski FB; Almeida BDS; Souza HFS; Ferreira NS; Maeda DLNF; Sales NS; Rosa DS; Ferreira LCS; Boscardin SB
    Front Immunol; 2019; 10():59. PubMed ID: 30761131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
    Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and Functional Characterization of a Cross-Reactive Dengue Virus Neutralizing Antibody that Recognizes a Cryptic Epitope.
    Li J; Watterson D; Chang CW; Che XY; Li XQ; Ericsson DJ; Qiu LW; Cai JP; Chen J; Fry SR; Cheung STM; Cooper MA; Young PR; Kobe B
    Structure; 2018 Jan; 26(1):51-59.e4. PubMed ID: 29249606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
    Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
    BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.